Review
Oncology
Allison M. Bock, Grzegorz S. Nowakowski, Yucai Wang
Summary: Despite challenges in treating R/R NHL, CD20 x CD3 BsAbs have shown promising efficacy with reduced toxicity. With ongoing expansion and registrational studies, approvals for R/R NHL treatment are expected soon. Further exploration is needed to determine the role of BsAbs in treatment-naive NHL and how to combine them with other therapies, as well as to compare and sequence BsAbs with CAR T-cell therapy.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Review
Hematology
Carrie Ho, Marco Ruella, Bruce L. Levine, Jakub Svoboda
Summary: Although CAR T-cell therapy has been approved for B-cell non-Hodgkin lymphomas, the progress for classic Hodgkin lymphoma (cHL) has been slower. Early clinical trials have shown promising clinical responses with the use of Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells in cHL patients, and research on CD19 and CD123 CAR T cells targeting the immunosuppressive tumor microenvironment in cHL is ongoing.
Review
Health Care Sciences & Services
Sean Harrop, Chathuri Abeyakoon, Carrie Van der Weyden, H. Miles Prince
Summary: T-cell lymphomas, rare and unsatisfactorily treated, have shown progress in targeted therapies due to advancements in understanding T-cell lymphogenesis pathways and identifying therapeutic targets. New treatments include antibody-based, small molecule inhibitors, and immune-based therapies.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Immunology
Pooya Farhangnia, Shiva Dehrouyeh, Amir Reza Safdarian, Soheila Vasheghani Farahani, Melika Gorgani, Nima Rezaei, Mahzad Akbarpour, Ali-Akbar Delbandi
Summary: The emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic have highlighted the urgent need for effective treatments. While various vaccines have been developed, their long-term efficacy in humans remains to be fully investigated. COVID-19 vaccination efforts face challenges such as financial and political obstacles, serious adverse effects, limitations in certain populations, and the emergence of viral variants. Passive immunotherapy is considered a promising complementary approach to managing COVID-19 by reducing inflammation, modulating the immune response, and neutralizing the virus.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Veterinary Sciences
Joana N. R. Dias, Ana S. Andre, Sandra I. I. Aguiar, Solange Gil, Luis Tavares, Frederico Aires-da-Silva
Summary: The new era of immune-oncology presents challenges and opportunities, with the use of a canine model in cancer immunotherapy drug development being widely recognized. Comparative research between human and canine NHL can provide valuable insights into treatment strategies. Additionally, the canine model may help bridge the gap between preclinical studies and clinical trials.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Review
Oncology
Diede A. G. van Bladel, Wendy B. C. Stevens, Michiel van den Brand, Leonie Kroeze, Patricia J. T. A. Groenen, J. Han J. M. van Krieken, Konnie M. Hebeda, Blanca Scheijen
Summary: This review provides an overview of recent advances in genotyping the clonal and mutational landscape of classical Hodgkin lymphoma (cHL). The authors discuss the application of next-generation sequencing in the diagnosis and treatment of cHL, as well as its contribution to understanding the pathogenesis of cHL.
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Letter
Immunology
Janina Trauth, Thomas Discher, Moritz Fritzenwanker, Can Imirzalioglu, Tobias Arnold, Dagmar Steiner, Elvira Richter, Laura Crisponi, Bodo Grimbacher, Susanne Herold
Summary: Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, usually occurs in heavily immunocompromised patients. We report a case of disseminated M. genavense infection preceding Hodgkin lymphoma in a patient without obvious risk factors for this infection.
EMERGING INFECTIOUS DISEASES
(2022)
Review
Oncology
Fauzia Ullah, Danai Dima, Najiullah Omar, Olisaemeka Ogbue, Sairah Ahmed
Summary: Hodgkin lymphoma (HL) is a rare type of lymphoma, with two subtypes: classical Hodgkin's lymphoma (cHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). cHL is highly curable with first-line chemotherapy, but some patients may relapse or fail to respond. High dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) is the standard treatment modality for chemo sensitive cHL. Targeted immunotherapy, novel agents, and CAR T-cell therapy are being explored as potential treatment options.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Christine Moore Smith, Debra L. Friedman
Summary: Since the 1950s, the treatment of Hodgkin lymphoma has been evolving, balancing cure and toxicity. Recent advancements in targeted therapies and immunotherapies are changing the landscape. Collaborations and patient-reported outcomes play important roles in driving scientific progress and improving treatment outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Stephanie Durand-Panteix, Jacques Monteil, Magali Sage, Armand Garot, Marie Clavel, Amal Saidi, Julien Torgue, Michel Cogne, Isabelle Quelven
Summary: This study investigated the potential of alpha-RIT in combination with Pb-212-rituximab for NHL treatment using mouse lymphoma cells. Results showed significant tumor regression and increased survival using 277.5 kBq Pb-212-rituximab, highlighting the potency of alpha-RIT for NHL treatment.
BRITISH JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
G. Manson, P. Brice, C. Herbaux, M. G. Silva, K. Bouabdallah, B. Deau, J. Bouteloup, J. M. Schiano, E. Nicolas-Virelizier, M. Maerevoet, H. Ghesquieres, A. Stamatoullas, C. Antier, C. Carlo-Stella, M. de Charette, F. Poizeau, L. Dercle, Roch Houot
Summary: This study investigated the optimal duration of treatment and the risk of relapse after anti-PD1 therapy in patients with R/R HL. A machine learning algorithm was used to predict PFS, with age, time to best response, and response quality identified as important variables.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Hematology
Alex F. Herrera, Joycelynne Palmer, Vikram Adhikarla, Dave Yamauchi, Erasmus K. Poku, James Bading, Paul Yazaki, Savita Dandapani, Matthew Mei, Robert Chen, Thai Cao, Nicole Karras, Pamela McTague, Auayporn Nademanee, Leslie Popplewell, Firoozeh Sahebi, John E. Shively, Jennifer Simpson, D. Lynne Smith, Joo Song, Ricardo Spielberger, Ni-Chun Tsai, Sandra H. Thomas, Stephen J. Forman, David Colcher, Anna M. Wu, Jeffrey Wong, Eileen Smith
Summary: In this study, the addition of 90Y-antiCD25 (aTac) to BEAM AHCT for high-risk relapsed or refractory classical Hodgkin lymphoma (HL) patients was shown to be safe and effective, with favorable outcomes observed in terms of toxicity, engraftment, and overall survival. Further evaluation of this approach in a phase 2 trial is ongoing to assess its efficacy.
Review
Oncology
Michael Maranzano, Monica Mead
Summary: Despite the successful use of frontline anthracycline-based chemotherapy for cHL, a significant portion of patients do not respond adequately and require additional therapy. AutoHCT can provide a lasting response for 50% of transplant-eligible patients, while alloHCT may be necessary for refractory patients. The use of salvage therapy, including chemotherapy and novel agents, has expanded the applicability of transplantation. Rating: 8/10
FRONTIERS IN ONCOLOGY
(2023)
Article
Medical Informatics
Anna M. Sawka, Sharon Straus, Gary Rodin, Richard W. Tsang, James D. Brierley, Lorne Rotstein, Phillip Segal, Amiram Gafni, Shereen Ezzat, David P. Goldstein
BMC MEDICAL INFORMATICS AND DECISION MAKING
(2015)
Article
Hematology
Shane A. Gangatharan, Manjula Maganti, John G. Kuruvilla, Vishal Kukreti, Rodger E. Tiedemann, Mary K. Gospodarowicz, David C. Hodgson, Alex Sun, Richard W. Tsang, Melania Pintilie, Michael Crump
BRITISH JOURNAL OF HAEMATOLOGY
(2015)
Article
Oncology
Anna M. Sawka, Sharon Straus, Gary Rodin, Lineke Heus, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, Phillip Segal, Amiram Gafni, Kevin E. Thorpe, David P. Goldstein
Article
Oncology
Maja V. Maraldo, Bouthaina S. Dabaja, Andrea R. Filippi, Tim Illidge, Richard Tsang, Umberto Ricardi, Peter M. Petersen, Deborah A. Schut, John Garcia, Jayne Headley, Amy Parent, Benoit Guibord, Riccardo Ragona, Lena Specht
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2015)
Article
Oncology
Jacqueline L. Bender, David Wiljer, Anna M. Sawka, Richard Tsang, Nour Alkazaz, James D. Brierley
SUPPORTIVE CARE IN CANCER
(2016)
Letter
Oncology
Anna M. Sawka, Richard W. Tsang, James D. Brierley, Lorne Rotstein, Phillip Segal, Shereen Ezzat, David P. Goldstein
Article
Oncology
Lynn Million, Esther J. Yi, Frank Wu, Rie Von Eyben, Belinda A. Campbell, Bouthaina Dabaja, Richard W. Tsang, Andrea Ng, Lynn D. Wilson, Umberto Ricardi, Youlia Kirova, Richard T. Hoppe
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2016)
Letter
Endocrinology & Metabolism
Anna M. Sawka, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, David P. Goldstein
Article
Oncology
Ezra Hahn, Haiyan Jiang, Angela Ng, Shaheena Bashir, Sameera Ahmed, Richard Tsang, Alexander Sun, Mary Gospodarowicz, David Hodgson
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2017)
Article
Otorhinolaryngology
Jason J. Xu, Eugene Yu, Caitlin McMullen, Jesse Pasternak, Jim Brierley, Richard Tsang, Han Zhang, Antoine Eskander, Lorne Rotstein, Anna M. Sawka, Ralph Gilbert, Jonathan Irish, Patrick Gullane, Dale Brown, John R. de Almeida, David P. Goldstein
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2017)
Article
Oncology
Haowei (Linda) Sun, Eshetu G. Atenafu, Richard Tsang, Vishal Kukreti, Theodore K. Marras, Michael Crump, John Kuruvilla
LEUKEMIA & LYMPHOMA
(2017)
Letter
Biophysics
Umberto Falcone, Haiyan Jiang, Shaheena Bashir, Richard Tsang, Vishal Kukreti, Armand Keating, Michael Crump, John Kuruvilla
BONE MARROW TRANSPLANTATION
(2018)
Article
Oncology
J. L. Hamilton, S. Foxcroft, E. Moyo, J. Cooke-Lauder, T. Spence, P. Zahedi, A. Bezjak, D. Jaffray, C. Lam, D. Letourneau, M. Milosevic, R. Tsang, R. Wong, F. F. Liu
Article
Oncology
B. S. Dabaja, A. D. Zelenetz, A. K. Ng, R. W. Tsang, S. Qi, P. K. Allen, D. Hodgson, U. Ricardi, R. T. Hoppe, R. Advani, P. M. Mauch, L. S. Constine, L. Specht, Y. Li, S. A. Terezakis, A. Wirth, G. Reinartz, H. T. Eich, B. M. P. Aleman, P. Barr, J. Yahalom
ANNALS OF ONCOLOGY
(2017)
Article
Oncology
H. Vulpe, J. Y. Y. Kwan, A. McNiven, J. D. Brierley, R. Tsang, B. Chan, D. P. Goldstein, L. W. Le, A. Hope, M. Giuliani